Ansuvimab for hemorrhagic fever, ebola

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Mar 2021: Trial registered, NCT04822376

The trials

NCT04822376: Prophylaxis Vaccine Antibodies Ebola

State
State not given
Phase
Phase 2
People
250 planned
Started
17 Oct 2021
Primary completion
Apr 2022
Arms
High risk arm, High risk arm (Immunological ancillary study)
Results
None posted
  1. 30 Mar 2021: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.